Response to COVID-19 vaccination in patients on cancer therapy: Analysis in a SARS-CoV-2-naïve population.

George CavicAndrew A AlmonteSarah M HicksTeresa NeemanJo-Wai WangSue BrewPhilip Y ChoiIan CockburnElizabeth E GardinerDesmond YipAude M FahrerYada Kanjanapan

Published in: Asia-Pacific journal of clinical oncology (2024)

Most patients and all controls became seropositive after two vaccine doses. Antibody concentrations and seropositivity showed a decrease between 1 and 3 months post vaccination, highlighting need for booster vaccinations. SARS-CoV-2 infection amplifies S-RBD antibody responses; however, cannot be adequately identified using nucleocapsid serology. This underlines the value of our COVID-naïve population in studying vaccine immunogenicity.

Keyphrases

sars cov
end stage renal disease
coronavirus disease
ejection fraction
respiratory syndrome coronavirus
newly diagnosed
chronic kidney disease
cancer therapy
prognostic factors
peritoneal dialysis